We've built a new version of this page with an interactive 3D viewer. Try it out in beta and help us improve:

› 7wcv

X-ray diffraction
2.3Å resolution

Co-crystal structure of FTO bound to 6e

Released:
DOI: 10.2210/pdb7wcv/pdb
Model geometry
Fit model/data
PDB entry 7wcv coloured by chain, front view.
PDB entry 7wcv coloured by chain, side view.
PDB entry 7wcv coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Structure-Activity Relationships and Antileukemia Effects of the Tricyclic Benzoic Acid FTO Inhibitors.
Liu Z, Duan Z, Zhang D, Xiao P, Zhang T, Xu H, Wang CH, Rao GW, Gan J, Huang Y, Yang CG, Dong Z
J Med Chem (2022)
PMID: 35793358

Function and Biology Details

Reaction catalysed: 
an N(6)-methyladenosine in mRNA + 2-oxoglutarate + O2 = an adenosine inmRNA + formaldehyde + succinate + CO2.
Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
monomeric (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-189888 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Alpha-ketoglutarate-dependent dioxygenase FTO Chain: A
Molecule details ›
Chain: A
Length: 491 amino acids
Theoretical weight: 56.46 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: Q9C0B1 (Residues: 32-505; Coverage: 94%)
  • Best match: Q9C0B1-4 (Residues: 1-106)
Gene names: FTO, KIAA1752
Sequence domains:

Ligands and Environments

3 bound ligands:
Ligand AKG 1 x AKG
Ligand MN 1 x MN
Ligand 943 1 x 943
No modified residues

Experiments and Validation Details

wwPDB Validation report is not available for this entry.
X-ray source: SSRF BEAMLINE BL17U1
Spacegroup: R3
Unit cell:
a: 141.759Å b: 141.759Å c: 83.74Å
α: 90° β: 90° γ: 120°
R-values:
R R work R free
0.204 0.202 0.241
Expression system: Escherichia coli

Quick links

Citations

1 review citation

Emerging roles of m6A RNA modification in cancer therapeutic resistance.
Liu et al. (2023)
1 other article